Brief Report

Pediatric Nephrology

, Volume 21, Issue 5, pp 729-732

Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists

  • Farida Daïkha-DahmaneAffiliated withService d’Anatomie Pathologique/Unité de Foetopathologie, Centre Hospitalier de Poissy-Saint Germain en Laye Email author 
  • , Evelyne Levy-BeffAffiliated withService d’Anatomie Pathologique/Unité de Foetopathologie, Centre Hospitalier de Poissy-Saint Germain en Laye
  • , Myriam JugieAffiliated withService de Réanimation Néonatale, Centre Hospitalier de Poissy-Saint Germain en Laye
  • , Richard LenclenAffiliated withService de Réanimation Néonatale, Centre Hospitalier de Poissy-Saint Germain en Laye

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

We report renal lesions observed in a foetus exposed throughout pregnancy to angiotensin II type I (AT 1) receptor antagonists. The mother suffered from essential hypertension and was treated with Cozaar (losartan 50 mg). Autopsy examination of the foetus revealed severe renal lesions, including tubular dysgenesis, hypertrophy of the endothelial and medial cells lining the arterial and arteriolar walls, hyperplasia of the juxtaglomerular apparatus and poorly developed vasa recta. Similar lesions have already been observed in foetuses of women treated with angiotensin-converting enzyme antagonists and also in foetuses and neonates of animals undergoing experimental blockade of the renin–angiotensin system. The purpose of this report is to describe structural lesions observed in the kidneys, and, particularly, vascular lesions. Our results suggest that the use of AT 1 receptor antagonists during pregnancy may have a severe deleterious effect on kidney development in the foetus.

Keywords

Fetal kidney AT 1 receptor antagonists Pregnancy